Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive readouts from its clinical trials, two powerful collaborators in its corner, and a strong balance sheet, Intellia has a lot of elements traditionally associated with biotechs having a high chance of success. 

And that means it could be smart to buy a few shares, especially if you're willing to hold for a few years until it has a chance to get one of its medicines out the door. So here's what you need to know about how and why it's well- positioned to grow.

On June 11, Intellia reported interim data from its phase 1/2 gene-editing therapy trial investigating its therapy for hereditary angioedema (HAE), and the results appear to be stellar so far.

Continue reading

Source Fool.com